Recent advances in the mechanism of pyridoxine-responsive disorders.
Pyridoxine metabolism is summarised and speculation on possible defects leading to disease is made. Inherited deficiencies of PLP enzymes, which are known to respond in vivo to pharmacologic doses of pyridoxine are listed. The mechanism of pyridoxine responsiveness in homocystinuria due to cystathionine beta-synthase deficiency is discussed. There is a correlation in most (but not all) cases between the presence of residual CS activity, which is often stimulated by pyridoxal phosphate much more than control enzyme, in cultured fibroblasts and pyridoxine responsiveness in vivo. Exceptional patients have been found and are discussed in the light of more detailed studies on their cell lines. Clearly defined abnormalities of pyridoxal phosphate binding to mutant enzyme have been demonstrated and evidence of reduced intracellular stability of mutant CS and possible modulation by pyridoxal phosphate is presented. Preliminary findings suggest that the tissue level of pyridoxal phosphate achieved following pyridoxine treatment could be one other factor in determining pyridoxine responsiveness.
D002478:Cells, Cultured; D003541:Cystathionine beta-Synthase / Q000172:deficiency*; D005347:Fibroblasts / Q000201:enzymology; D006712:Homocystinuria / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D006801:Humans; D006836:Hydro-Lyases / Q000172:deficiency*; D011732:Pyridoxal Phosphate / Q000097:blood / Q000627:therapeutic use; D011736:Pyridoxine / Q000378:metabolism / Q000627:therapeutic use*
D011732:Pyridoxal Phosphate; D006836:Hydro-Lyases; D003541:Cystathionine beta-Synthase; D011736:Pyridoxine